Biologic Utilization Patterns: Data from the International Severe Asthma Registry (ISAR)

Andrew Menzies-Gow, Wang Eileen, Mari-Anne Rowlands, Marianna Alacqua, Mona Al-Ahmad, Lakmini Bulathsinhala, Victoria Carter, Isha Chaudhry, Borja G. Cosio, Nevaashni Eleangovan, J. Mark FitzGerald, Liam G Heaney, Mark Hew, Naeimeh Hosseini, David Jackson, Maria Kallieri, Désirée Larenas-Linnemann, Stelios Loukides, Njira Lugogo, Ruth B MurrayAndriana I. Papaioannou, Luis Perez de Llano, Celeste Porsbjerg, Linda M. Rasmussen, Johannes Schmid, Trung N Tran, Charlotte Ulrik, John W Upham, David Price

Research output: Contribution to conferenceAbstractpeer-review

Abstract

Use of biologics in severe asthma has grown dramatically in the last decade. However, little is known about the patterns of biologic use in real-life. Our aim was to describe frequency and patterns of biologic use in an international severe asthma cohort.
Original languageEnglish
Publication statusPublished - 20 Mar 2021
Event6th REG Summit: The Respiratory Effectiveness Group - Virtual
Duration: 18 Mar 202120 Mar 2021
Conference number: 6th
https://www.erasmus.gr/microsites/1218

Conference

Conference6th REG Summit
Period18/03/2120/03/21
Internet address

Bibliographical note

Funding: ISAR is conducted by Optimum Patient Care (OPC) Global Limited, and co-funded by OPC Global and AstraZeneca

Fingerprint

Dive into the research topics of 'Biologic Utilization Patterns: Data from the International Severe Asthma Registry (ISAR)'. Together they form a unique fingerprint.

Cite this